Marker Therapeutics (MRKR) Set to Post Earnings on Thursday

Marker Therapeutics (NASDAQ:MRKR) is expected to be releasing its Q3 2026 resultson Thursday, November 12th. Analysts expect Marker Therapeutics to announce earnings of ($0.1167) per share and revenue of $2.12 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Marker Therapeutics (NASDAQ:MRKR) last posted its earnings results on Friday, August 14th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.16. On average, analysts expect Marker Therapeutics to post ($0.64) EPS for the current fiscal year and ($1.23) EPS for the next fiscal year.

Marker Therapeutics Trading Up 10.9%

Shares of MRKR stock opened at $0.99 on Tuesday. The firm has a market capitalization of $16.51 million, a price-to-earnings ratio of -2.42 and a beta of 1.65. The business’s 50-day moving average price is $1.08 and its 200-day moving average price is $1.34. Marker Therapeutics has a 12 month low of $0.84 and a 12 month high of $2.46.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on MRKR shares. Zacks Research upgraded shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. Weiss Ratings raised shares of Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 19th. Finally, HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors.

The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.